Fibroblast growth factor 21 may be a strong biomarker for renal outcomes: a meta-analysis

References

• Woo YC, Xu A, Wang Y, et al. Fibroblast growth factor 21 as an emerging metabolic regulator: clinical perspectives. Clin Endocrinol. 2013;78(4):489–496.
   PubMed Web of Science ®Google Scholar
• Gaich G, Chien JY, Fu H, et al. The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes. Cell Metab. 2013;18(3):333–340.
   PubMed Web of Science ®Google Scholar
• Li H, Fang Q, Gao F, et al. Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride. J Hepatol. 2010;53(5):934–940.
   PubMed Web of Science ®Google Scholar
• Lin Z, Wu Z, Yin X, et al. Serum levels of FGF-21 are increased in coronary heart disease patients and are independently associated with adverse lipid profile. PLOS One. 2010;5(12):e15534.
   PubMed Web of Science ®Google Scholar
• Chavez AO, Molina-Carrion M, Abdul-Ghani MA, et al. Circulating fibroblast growth factor-21 is elevated in impaired glucose tolerance and type 2 diabetes and correlates with muscle and hepatic insulin resistance. Diabetes Care. 2009;32(8):1542–1546.
   PubMed Web of Science ®Google Scholar
• Zhang X, Yeung DCY, Karpisek M, et al. Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes. 2008;57(5):1246–1253.
   PubMed Web of Science ®Google Scholar
• Chen C, Cheung BMY, Tso AWK, et al. High plasma level of fibroblast growth factor 21 is an independent predictor of type 2 diabetes: a 5.4-year population-based prospective study in Chinese subjects. Diabetes Care. 2011;34(9):2113–2115.
   PubMed Web of Science ®Google Scholar
• Hindricks J, Ebert T, Bachmann A, et al. Serum levels of fibroblast growth factor-21 are increased in chronic and acute renal dysfunction. Clin Endocrinol. 2014;80(6):918–924.
   PubMed Web of Science ®Google Scholar
• Lin Z, Zhou Z, Liu Y, et al. Circulating FGF21 levels are progressively increased from the early to end stages of chronic kidney diseases and are associated with renal function in Chinese. PLOS One. 2011;6(4):e18398.
   PubMed Web of Science ®Google Scholar
• Jian W-X, Peng W-H, Jin J, et al. Association between serum fibroblast growth factor 21 and diabetic nephropathy. Metabolism. 2012;61(6):853–859.
   PubMed Web of Science ®Google Scholar
• Kalantar-Zadeh K, Jafar TH, Nitsch D, et al. Chronic kidney disease. Lancet. 2021;398(10302):786–802.
   PubMed Web of Science ®Google Scholar
• Boris B, Caroline A, Andrew S, et al. Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the global burden of disease study 2017. Lancet. 2020;395(10225):709–733.
   PubMed Web of Science ®Google Scholar
• Hu Q, Chen Y, Bao T, et al. Association of metabolic dysfunction-associated fatty liver disease with chronic kidney disease: a Chinese population-based study. Ren Fail. 2022;44(1):1996–2005.
   PubMed Web of Science ®Google Scholar
• Zhou X, Zhang Y, Wang N. Regulation and potential biological role of fibroblast growth factor 21 in chronic kidney disease. Front Physiol. 2021;12:764503.
   PubMed Web of Science ®Google Scholar
• Matsushita K, van der Velde M, Astor BC, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010;375(9731):2073–2081.
   PubMed Web of Science ®Google Scholar
• Anuwatmatee S, Tang S, Wu BJ, et al. Fibroblast growth factor 21 in chronic kidney disease. Clin Chim Acta. 2019;489:196–202.
   PubMed Web of Science ®Google Scholar
• Angelin B, Larsson TE, Rudling M. Circulating fibroblast growth factors as metabolic regulators – a critical appraisal. Cell Metab. 2012;16(6):693–705.
   PubMed Web of Science ®Google Scholar
• Kharitonenkov A, Adams AC. Inventing new medicines: the FGF21 story. Mol Metab. 2014;3(3):221–229.
   PubMed Web of Science ®Google Scholar
• Kondo Y, Komaba H, Fukagawa M. Endocrine fibroblast growth factors as potential biomarkers for chronic kidney disease. Expert Rev Mol Diagn. 2020;20(7):715–724.
   PubMed Web of Science ®Google Scholar
• Lee CH, Hui EYL, Woo YC, et al. Circulating fibroblast growth factor 21 levels predict progressive kidney disease in subjects with type 2 diabetes and normoalbuminuria. J Clin Endocrinol Metab. 2015;100(4):1368–1375.
   PubMed Web of Science ®Google Scholar
• Parums DV. Editorial: review articles, systematic reviews, meta-analysis, and the updated preferred reporting items for systematic reviews and meta-analyses (PRISMA) 2020 guidelines. Med Sci Monit. 2021;27:e934475.
   PubMed Web of Science ®Google Scholar
• Prischl FC, Wanner C. Renal outcomes of antidiabetic treatment options for type 2 diabetes-A proposed MARE definition. Kidney Int Rep. 2018;3(5):1030–1038.
   PubMed Web of Science ®Google Scholar
• Chang L-H, Hwu C-M, Chu C-H, et al. The combination of soluble tumor necrosis factor receptor type 1 and fibroblast growth factor 21 exhibits better prediction of renal outcomes in patients with type 2 diabetes mellitus. J Endocrinol Invest. 2021;44(12):2609–2619.
   PubMed Web of Science ®Google Scholar
• Crasto C, Semba RD, Sun K, et al. Serum fibroblast growth factor 21 is associated with renal function and chronic kidney disease in community-dwelling adults. J Am Geriatr Soc. 2012;60(4):792–793.
   PubMed Web of Science ®Google Scholar
• González E, Díez JJ, Bajo MA, et al. Fibroblast growth factor 21 (FGF-21) in peritoneal dialysis patients: natural history and metabolic implications. PLOS One. 2016;11(3):e0151698.
   PubMed Web of Science ®Google Scholar
• Han SH, Choi SH, Cho BJ, et al. Serum fibroblast growth factor-21 concentration is associated with residual renal function and insulin resistance in end-stage renal disease patients receiving long-term peritoneal dialysis. Metabolism. 2010;59(11):1656–1662.
   PubMed Web of Science ®Google Scholar
• Kohara M, Masuda T, Shiizaki K, et al. Association between circulating fibroblast growth factor 21 and mortality in end-stage renal disease. PLOS One. 2017;12(6):e0178971.
   PubMed Web of Science ®Google Scholar
• Reinhard M, Frystyk J, Jespersen B, et al. Response of fibroblast growth factor 21 to meal intake and insulin infusion in patients on maintenance haemodialysis. Clin Endocrinol. 2015;83(2):187–195.
   PubMed Web of Science ®Google Scholar
• Stein S, Bachmann A, Lössner U, et al. Serum levels of the adipokine FGF21 depend on renal function. Diabetes Care. 2009;32(1):126–128.
   PubMed Web of Science ®Google Scholar
• Gamrot Z, Adamczyk P, Świętochowska E, et al. Fibroblast growth factor 21 (FGF21) in children and adolescents with chronic kidney disease. Physiol Res. 2020;69(3):451–460.
   PubMed Web of Science ®Google Scholar
• Ángel GM, et al. Fibroblast growth factor 21 is associated with increased serum total antioxidant capacity and oxidized lipoproteins in humans with different stages of chronic kidney disease. Ther Adv Endocrinol Metab. 2021;12:20420188211001160.
   Web of Science ®Google Scholar
• Wu C-H, Chou R-H, Kuo C-S, et al. Circulating fibroblast growth factor 21 is associated with subsequent renal injury events in patients undergoing coronary angiography. Sci Rep. 2018;8(1):12425.
   PubMedGoogle Scholar
• Wei N, Guo ZQ, Yang F. Changes and significance of serum FGF21 in children with primary nephrotic syndrome and chronic renal failure. Am J Transl Res. 2021;13(6):6126–6133.
   PubMed Web of Science ®Google Scholar
• Liu J-J, Liu S, Choo RWM, et al. Sex modulates the association of fibroblast growth factor 21 with end-stage renal disease in Asian people with type 2 diabetes: a 6.3-year prospective cohort study. Diabet Med. 2018;35(7):880–886.
   PubMed Web of Science ®Google Scholar
• Anuwatmatee S, Allison MA, Shlipak MG, et al. Relationship of fibroblast growth factor 21 with kidney function and albuminuria: multi-ethnic study of atherosclerosis. Nephrol Dial Transplant. 2019;34(6):1009–1016.
   PubMed Web of Science ®Google Scholar
• Marchelek-Myśliwiec M, Dziedziejko V, Nowosiad-Magda M, et al. Chronic kidney disease is associated with increased plasma levels of fibroblast growth factors 19 and 21. Kidney Blood Press Res. 2019;44(5):1207–1218.
   PubMed Web of Science ®Google Scholar
• Bagheri L, Hami M, Mojahedi M-J, et al. Association of metabolic syndrome with serum fibroblast growth factor 21 in kidney transplanted patients. J Renal Inj Prev. 2016;5(2):79–84.
   PubMedGoogle Scholar
• Trakarnvanich T, Prommool S, Kurathong S, et al. Associations among cardio-ankle vascular index, carotid intima-media thickness, and fibroblast growth factor-21 levels in kidney transplant patients. Transplant Proc. 2017;49(8):1791–1796.
   PubMed Web of Science ®Google Scholar
• Kharitonenkov A, Shiyanova TL, Koester A, et al. FGF-21 as a novel metabolic regulator. J Clin Invest. 2005;115(6):1627–1635.
   PubMed Web of Science ®Google Scholar
• Holland WL, Adams AC, Brozinick JT, et al. An FGF21-adiponectin-ceramide axis controls energy expenditure and insulin action in mice. Cell Metab. 2013;17(5):790–797.
   PubMed Web of Science ®Google Scholar
• Kharitonenkov A, Wroblewski VJ, Koester A, et al. The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21. Endocrinology. 2007;148(2):774–781.
   PubMed Web of Science ®Google Scholar
• Coskun T, Bina HA, Schneider MA, et al. Fibroblast growth factor 21 corrects obesity in mice. Endocrinology. 2008;149(12):6018–6027.
   PubMed Web of Science ®Google Scholar
• Fisher FM, Chui PC, Antonellis PJ, et al. Obesity is a fibroblast growth factor 21 (FGF21)-resistant state. Diabetes. 2010;59(11):2781–2789.
   PubMed Web of Science ®Google Scholar